A detailed history of First Capital Advisors Group, Llc. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, First Capital Advisors Group, Llc. holds 100 shares of PCVX stock, worth $8,653. This represents 0.0% of its overall portfolio holdings.

Number of Shares
100
Holding current value
$8,653
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 15, 2023

BUY
$34.66 - $54.07 $3,465 - $5,407
100 New
100 $4,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.13B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track First Capital Advisors Group, Llc. Portfolio

Follow First Capital Advisors Group, Llc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Capital Advisors Group, Llc., based on Form 13F filings with the SEC.

News

Stay updated on First Capital Advisors Group, Llc. with notifications on news.